BNN-20 | CAS#847-75-6 | DHEA analogue

MedKoo Cat#: 145206 | Name: BNN-20

Description:

WARNING: This product is for research use only, not for human or veterinary use.

BNN-20 is a synthetic analogue of DHEA. BNN-20 has been identified as a potential therapeutic for Parkinson's disease (PD). Acute administration of BNN-20 in Weaver/NGL mice demonstrated a robust NF-κB-dependent transcriptional response in the brain. Long-term administration of BNN-20 protected dopaminergic neurons and their terminals.

Chemical Structure

BNN-20

CAS#847-75-6

Theoretical Analysis

MedKoo Cat#: 145206

Name: BNN-20

CAS#: 847-75-6

Chemical Formula: C20H30O2

Exact Mass: 302.2246

Molecular Weight: 302.46

Elemental Analysis: C, 79.42; H, 10.00; O, 10.58

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

BNN-20; BNN20; BNN 20;

IUPAC/Chemical Name

(3S,8R,9S,10R,13S,14S,17S)-10,13-dimethyl-1,2,3,4,7,8,9,10,11,12,13,14,15,16-tetradecahydrospiro[cyclopenta[a]phenanthrene-17,2'-oxiran]-3-ol

InChi Key

LKDLANDMNIFZOI-IJMQKCTASA-N

InChi Code

1S/C20H30O2/c1-18-8-5-14(21)11-13(18)3-4-15-16(18)6-9-19(2)17(15)7-10-20(19)12-22-20/h3,14-17,21H,4-12H2,1-2H3/t14-,15+,16-,17-,18-,19-,20+/m0/s1

SMILES Code

[H][C@@]12CC[C@@]3(CO3)[C@@]1(C)CC[C@@]4([H])[C@@]2([H])CC=C5C[C@@H](O)CC[C@]45C

Appearance

To be determined

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 -4 C for short term (days to weeks) or -20 C for long term(months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 302.46 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Botsakis K, Mourtzi T, Panagiotakopoulou V, Vreka M, Stathopoulos GT, Pediaditakis I, Charalampopoulos I, Gravanis A, Delis F, Antoniou K, Zisimopoulos D, Georgiou CD, Panagopoulos NT, Matsokis N, Angelatou F. BNN-20, a synthetic microneurotrophin, strongly protects dopaminergic neurons in the "weaver" mouse, a genetic model of dopamine-denervation, acting through the TrkB neurotrophin receptor. Neuropharmacology. 2017 Jul 15;121:140-157. doi: 10.1016/j.neuropharm.2017.04.043. Epub 2017 Apr 28. PMID: 28461162. 2: Mourtzi T, Dimitrakopoulos D, Kakogiannis D, Salodimitris C, Botsakis K, Meri DK, Anesti M, Dimopoulou A, Charalampopoulos I, Gravanis A, Matsokis N, Angelatou F, Kazanis I. Characterization of substantia nigra neurogenesis in homeostasis and dopaminergic degeneration: beneficial effects of the microneurotrophin BNN-20. Stem Cell Res Ther. 2021 Jun 10;12(1):335. doi: 10.1186/s13287-021-02398-3. PMID: 34112234; PMCID: PMC8193896. 3: Panagiotakopoulou V, Botsakis K, Delis F, Mourtzi T, Tzatzarakis MN, Dimopoulou A, Poulia N, Antoniou K, Stathopoulos GT, Matsokis N, Charalampopoulos I, Gravanis A, Angelatou F. Anti-neuroinflammatory, protective effects of the synthetic microneurotrophin BNN-20 in the advanced dopaminergic neurodegeneration of "weaver" mice. Neuropharmacology. 2020 Mar 15;165:107919. doi: 10.1016/j.neuropharm.2019.107919. Epub 2019 Dec 23. PMID: 31877321. 4: Mourtzi T, Antoniou N, Dimitriou C, Gkaravelas P, Athanasopoulou G, Kostantzo PN, Stathi O, Theodorou E, Anesti M, Matsas R, Angelatou F, Kouroupi G, Kazanis I. Enhancement of endogenous midbrain neurogenesis by microneurotrophin BNN-20 after neural progenitor grafting in a mouse model of nigral degeneration. Neural Regen Res. 2024 Jun 1;19(6):1318-1324. doi: 10.4103/1673-5374.385314. Epub 2023 Sep 22. PMID: 37905881. 5: Anesti M, Magkafa S, Prantikou E, Kazanis I. Divergence between Neuronal and Oligodendroglial Cell Fate, in Postnatal Brain Neural Stem Cells, Leads to Divergent Properties in Polymorphic In Vitro Assays. Cells. 2022 May 25;11(11):1743. doi: 10.3390/cells11111743. PMID: 35681436; PMCID: PMC9179558.